+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome



An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome



Pediatric Infectious Disease Journal 28(4): 339-341



We examined the serum values of high mobility group box 1 (HMGB1) in 36 patients with Kawasaki syndrome (KS) (29 responders and 7 poor-responders to initial intravenous immunoglobulin treatment). A mean value of HMGB1 of poor-responders was significantly elevated compared with those of responders (P = 0.0042). Among the 6 factors showing significant differences between responders and poor-responders including HMGB1 (admission illness day, white blood cell counts, C-reactive protein, aspartate aminotransferase, lactate dehydrogenase), values of HMGB1 showed the widest area under the receiver operating characteristic curve. In conclusion, an elevated HMGB1 value could be a potential marker for poor-responders.

(PDF emailed within 0-6 h: $19.90)

Accession: 051481743

Download citation: RISBibTeXText

PMID: 19238112

DOI: 10.1097/INF.0b013e31818ffe60


Related references

Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clinical Pediatrics 41(8): 597-601, 2002

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Transfusion 58(11): 2564-2571, 2018

Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. Bmc Pediatrics 18(1): 200, 2018

Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226: 510-516, 2013

Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. Yonsei Medical Journal 55(5): 1260-1266, 2015

Treatment of Kawasaki's syndrome with high dose intravenous gammaglobulins. Pediatrie 41(1): 65-69, 1986

Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease. Journal of Pediatrics 148(3): 399-400, 2006

Psoriasis: Response to high-dose intravenous immunoglobulin in three patients. British Journal of Dermatology 147(3): 554-557, 2002

High-mobility group box 1 as a surrogate prognostic marker in dogs with systemic inflammatory response syndrome. Journal of Veterinary Emergency and Critical Care 20(3): 298-302, 2010

Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki disease. Acta Paediatrica 91(2): 164-167, 2002

Comparison of low dose aspirin lda vs high dose aspirin hda as an adjunct to intravenous gamma globulin ivig in the treatment of kawasaki syndrome ks. Pediatric Research 31(4 PART 2): 170A, 1992

Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Annals of Allergy, Asthma and Immunology 92(1): 80-87, 2004

Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Journal of Allergy and Clinical Immunology 88(5): 823-824, 1991

Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease. American Journal of Hematology 63(3): 160-161, 2000